- $2.95m
- -$5.59m
- $9.14m
Brief: Aravive Files For Mixed Shelf Of Up To $150 Mln
Brief: Aravive Inc Says Current Cash And Cash Equivalents Expected To Fund Operations Into 2022
Brief: Aravive Announces Successful Completion Of Phase 1B Trial Evaluating Avb-500 In Platinum Resistant Ovarian Cancer
Brief: Aravive Says Co Added To Russell 2000 And Russell 3000 Indexes
Brief: Aravive Files For Offer And Resale Of Up To 931,098 Shares By Selling Stockholder - SEC Filing
Brief: Aravive Says Rekha Hemrajani Has Resigned As CEO And As A Director
Brief: Aravive - Avb-500 Improves Anti-Tumor Effects When Combined With Anti-Angiogenic Bevacizumab Or Parp Inhibitor Olaparib For Uterine Cancer
Brief: Aravive Announces Initiation Of Investigator-Sponsored Phase 1/2 Study Of AVB-500 In Combination With Avelumab
Nasdaq Trade Halt Market Wide Circuit Breaker Halt: LEVEL 1 AT 08:35 AM
Brief: Inovio Welcomes Jay Shepard To Its Board Of Directors
Brief: Aravive Receives IND Clearance For Phase 1B/Phase 2 Clinical Trial Of AVB-500
Brief: Aravive Says Jay Shepard To Assume Role Of Chairman Of Board
Brief: Aravive Initiates A Phase 2A Clinical Trial Of AVB-500 In Patients With Kidney Fibrosis
U.S. STOCKS ON THE MOVE-regular hours
U.S. STOCKS ON THE MOVE-Box, My Size, Alibaba, Under Armour
U.S. STOCKS ON THE MOVE-Aravive, Under Armour, Dell, AVX
U.S. STOCKS ON THE MOVE-Aravive, Guess, Safe-T, Under Armour
Brief: Aravive Announces Pricing Of Public Offering Of Common Stock
Biotech Aravive drops after pricing deep-discounted stock offering